News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
741,831 Results
Type
Article (43797)
Company Profile (318)
Press Release (697703)
Multimedia
Podcasts (116)
Webinars (19)
Section
Business (210989)
Career Advice (2107)
Deals (36757)
Drug Delivery (123)
Drug Development (83416)
Employer Resources (176)
FDA (16822)
Job Trends (15501)
News (357352)
Policy (34126)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2612)
Accelerated approval (32)
Adcomms (26)
Allergies (148)
Alliances (51586)
ALS (173)
Alzheimer's disease (1690)
Antibody-drug conjugate (ADC) (323)
Approvals (17086)
Artificial intelligence (537)
Autoimmune disease (156)
Automation (39)
Bankruptcy (372)
Best Places to Work (11771)
BIOSECURE Act (21)
Biosimilars (195)
Biotechnology (188)
Bladder cancer (157)
Brain cancer (60)
Breast cancer (648)
Cancer (4877)
Cardiovascular disease (413)
Career advice (1786)
Career pathing (37)
CAR-T (286)
CDC (47)
Celiac Disease (2)
Cell therapy (757)
Cervical cancer (36)
Clinical research (71151)
Collaboration (1759)
Company closure (4)
Compensation (1166)
Complete response letters (62)
COVID-19 (2784)
CRISPR (95)
C-suite (868)
Cystic fibrosis (148)
Data (6257)
Decentralized trials (2)
Denatured (36)
Depression (134)
Diabetes (506)
Diagnostics (6773)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (261)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (233)
Earnings (91898)
Editorial (60)
Employer branding (21)
Employer resources (155)
Events (120218)
Executive appointments (998)
FDA (19970)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1484)
Gene editing (202)
Generative AI (45)
Gene therapy (615)
GLP-1 (1014)
Government (4802)
Grass and pollen (7)
Guidances (384)
Healthcare (19059)
HIV (58)
Huntington's disease (45)
IgA nephropathy (85)
Immunology and inflammation (261)
Immuno-oncology (58)
Indications (111)
Infectious disease (3054)
Inflammatory bowel disease (194)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (253)
Interviews (326)
IPO (16920)
IRA (57)
Job creations (4069)
Job search strategy (1498)
JPM (64)
Kidney cancer (16)
Labor market (85)
Layoffs (575)
Leadership (33)
Legal (8424)
Liver cancer (92)
Longevity (15)
Lung cancer (654)
Lymphoma (379)
Machine learning (43)
Management (60)
Manufacturing (821)
MASH (169)
Medical device (13855)
Medtech (13908)
Mergers & acquisitions (20907)
Metabolic disorders (1303)
Multiple sclerosis (160)
NASH (17)
Neurodegenerative disease (321)
Neuropsychiatric disorders (91)
Neuroscience (2943)
Neurotech (1)
NextGen: Class of 2026 (6644)
Non-profit (4563)
Now hiring (67)
Obesity (616)
Opinion (283)
Ovarian cancer (167)
Pain (216)
Pancreatic cancer (228)
Parkinson's disease (281)
Partnered (34)
Patents (503)
Patient recruitment (494)
Peanut (59)
People (60900)
Pharmaceutical (90)
Pharmacy benefit managers (31)
Phase 1 (22084)
Phase 2 (31283)
Phase 3 (23441)
Pipeline (5318)
Policy (297)
Postmarket research (2655)
Preclinical (9383)
Press Release (68)
Prostate cancer (239)
Psychedelics (50)
Radiopharmaceuticals (285)
Rare diseases (866)
Real estate (6305)
Recruiting (72)
Regulatory (25382)
Reports (52)
Research institute (2438)
Resumes & cover letters (361)
Rett syndrome (27)
RNA editing (17)
RSV (77)
Schizophrenia (156)
Series A (244)
Series B (193)
Service/supplier (11)
Sickle cell disease (99)
Special edition (24)
Spinal muscular atrophy (160)
Sponsored (42)
Startups (3765)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (96)
The Weekly (78)
Vaccines (1033)
Venture capital (90)
Weight loss (404)
Women's health (91)
Worklife (18)
Date
Today (105)
Last 7 days (620)
Last 30 days (2148)
Last 365 days (30377)
2026 (3471)
2025 (30679)
2024 (35769)
2023 (40630)
2022 (51799)
2021 (56329)
2020 (54794)
2019 (47400)
2018 (35772)
2017 (33136)
2016 (32663)
2015 (38617)
2014 (32517)
2013 (27632)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (800)
Alabama (83)
Alaska (7)
Arizona (317)
Arkansas (14)
Asia (42156)
Australia (6747)
California (11349)
Canada (3309)
China (1139)
Colorado (480)
Connecticut (478)
Delaware (340)
Europe (90352)
Florida (1695)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (877)
India (68)
Indiana (529)
Iowa (22)
Japan (442)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1391)
Massachusetts (8174)
Michigan (327)
Minnesota (632)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (123)
New Hampshire (78)
New Jersey (3019)
New Mexico (29)
New York (2994)
North Carolina (1475)
North Dakota (8)
Northern California (5535)
Ohio (335)
Oklahoma (22)
Oregon (46)
Pennsylvania (2294)
Puerto Rico (24)
Rhode Island (48)
South America (1175)
South Carolina (67)
South Dakota (1)
Southern California (4418)
Tennessee (174)
Texas (1755)
United States (40340)
Utah (337)
Vermont (1)
Virginia (276)
Washington D.C. (81)
Washington State (928)
West Virginia (4)
Wisconsin (113)
Wyoming (2)
741,831 Results for "napo pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
August 20, 2025
·
4 min read
Biotech Bay
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is a Bronze Sponsor of the 10th Annual Elite Ped-GI Congress, which takes place May 2-4, 2024 in Abu Dhabi in the United Arab Emirates (UAE).
April 29, 2024
·
6 min read
Press Releases
Napo Pharmaceuticals, a Jaguar Health Family Company, Exhibiting at the Oncology Nursing Society (ONS) Congress for the FDA-Approved Gelclair Oral Mucositis Prescription Product
April 8, 2025
·
9 min read
Biotech Bay
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced they were proud to provide fiscal support for More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer.
September 26, 2023
·
4 min read
Biotech Bay
Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company’s FDA-Approved Prescription Drug
Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual Association of Nurses in AIDS Care (ANAC) Conference.
October 18, 2023
·
5 min read
Press Releases
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
February 13, 2026
·
12 min read
Press Releases
Aucta Pharmaceuticals, Inc. (“Aucta Pharmaceuticals”) prepares for the launch of PYQUVI™ (deflazacort) oral suspension, the first of a new branded-generic rare disease product line
February 8, 2026
·
7 min read
Biotech Bay
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Napo Pharmaceuticals Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the activation by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for a new crofelemer powder for oral solution formulation for the treatment of microvillus inclusion disease (MVID), an ultra-rare congenital diarrheal disorder (CDD).
August 8, 2023
·
4 min read
Biotech Bay
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Napo Pharmaceuticals, Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral sclerosis (ALS), and the results of a corresponding Napo-sponsored survey of 15 US individuals who are either ALS patients or caregivers of an ALS patient.
August 16, 2023
·
6 min read
Biotech Bay
MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
Napo Pharmaceuticals, a Jaguar Health, Inc. family company, announced that a Multinational Association of Supportive Care in Cancer webinar titled “GI Toxicities from Cancer Therapies - Prevention and Management,” taking place Monday, January 29, 2024 from 11:30 AM to 12:30 PM Eastern Standard Time, was made possible by an unrestricted educational grant from Napo.
December 7, 2023
·
4 min read
1 of 74,184
Next
